EA201992646A1 - Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма - Google Patents

Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Info

Publication number
EA201992646A1
EA201992646A1 EA201992646A EA201992646A EA201992646A1 EA 201992646 A1 EA201992646 A1 EA 201992646A1 EA 201992646 A EA201992646 A EA 201992646A EA 201992646 A EA201992646 A EA 201992646A EA 201992646 A1 EA201992646 A1 EA 201992646A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases associated
steroids
therapy
application
treatment
Prior art date
Application number
EA201992646A
Other languages
English (en)
Russian (ru)
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Publication of EA201992646A1 publication Critical patent/EA201992646A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201992646A 2018-11-23 2019-11-22 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма EA201992646A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Publications (1)

Publication Number Publication Date
EA201992646A1 true EA201992646A1 (ru) 2020-05-31

Family

ID=69624712

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992646A EA201992646A1 (ru) 2018-11-23 2019-11-22 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Country Status (19)

Country Link
US (1) US20220362230A1 (enExample)
EP (2) EP4218758A3 (enExample)
JP (2) JP2022508167A (enExample)
KR (2) KR20220162821A (enExample)
CN (2) CN114652721A (enExample)
AU (2) AU2019384626A1 (enExample)
BR (1) BR112021009801A2 (enExample)
CA (1) CA3120882A1 (enExample)
CL (2) CL2021001316A1 (enExample)
EA (1) EA201992646A1 (enExample)
GE (4) GEAP202215712A (enExample)
IL (2) IL297533A (enExample)
MD (2) MD4844C1 (enExample)
MX (2) MX2021006032A (enExample)
MY (1) MY209416A (enExample)
PH (1) PH12021551152A1 (enExample)
RU (1) RU2712281C1 (enExample)
WO (1) WO2020106191A1 (enExample)
ZA (2) ZA202104247B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および2−アミノ−2’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
CN110128406B (zh) * 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines

Also Published As

Publication number Publication date
MD20210050A2 (ro) 2021-12-31
WO2020106191A1 (ru) 2020-05-28
EP4218758A2 (en) 2023-08-02
JP2022508167A (ja) 2022-01-19
JP7518997B2 (ja) 2024-07-19
MD4851B1 (ro) 2023-04-30
PH12021551152A1 (en) 2021-10-25
GEP20237467B (en) 2023-02-10
MD4844C1 (ro) 2023-09-30
MD4844B1 (ro) 2023-02-28
AU2019384626A1 (en) 2021-07-15
CN114652721A (zh) 2022-06-24
IL283317A (en) 2021-07-29
ZA202210444B (en) 2023-01-25
MX2022013503A (es) 2022-11-16
EP4218758A3 (en) 2023-08-23
JP2023015333A (ja) 2023-01-31
EP3884945A1 (en) 2021-09-29
CA3120882A1 (en) 2020-05-28
IL297533A (en) 2022-12-01
AU2022256212A1 (en) 2022-12-08
MD4851C1 (ro) 2023-11-30
KR20220162821A (ko) 2022-12-08
CL2022000683A1 (es) 2022-10-28
RU2712281C1 (ru) 2020-01-28
CN113164464A (zh) 2021-07-23
CL2021001316A1 (es) 2021-10-29
GEP20247643B (en) 2024-07-10
MX2021006032A (es) 2021-07-06
KR20210095652A (ko) 2021-08-02
MY209416A (en) 2025-07-08
US20220362230A1 (en) 2022-11-17
AU2022256212B2 (en) 2024-08-15
GEAP202215712A (en) 2022-10-10
GEAP202415619A (en) 2024-03-11
ZA202104247B (en) 2023-03-29
BR112021009801A2 (pt) 2022-03-03
EP3884945A4 (en) 2022-11-23
MD20210032A2 (ro) 2021-09-30

Similar Documents

Publication Publication Date Title
WO2019195810A3 (en) Atf6 inhibitors and uses thereof
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
MX391392B (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2019013693A (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteinas de las mismas.
MX2017013310A (es) Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico.
EA201992646A1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
SMT202400486T1 (it) Proteine di capside avv modificate per il trattamento della malattia artritica
MD20160102A2 (ro) Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
WO2016110806A3 (en) Dosage regimen for madcam antagonists
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EP3573616A4 (en) NOVEL SPIRO- AND CYCLIC BIS-BENZYLIDINE PROTEASOME INHIBITOR FOR TREATMENT OF CANCER, DIABETES AND NEUROLOGICAL DISORDERS
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
WO2022093552A8 (en) Rev-erb agonists
LT4118069T (lt) Parahidrochinono dariniai, tokie kaip vegf, tnf ir (arba) il inhibitoriai, skirti uždegiminėms nervų sistemos ligoms gydyti
EP3936184A4 (en) ELECTRICAL STIMULATION THERAPY ELECTRODE AND ELECTRICAL STIMULATION THERAPY DEVICE
EA201992341A8 (ru) Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
MX2021003274A (es) Combinacion farmaceutica para el tratamiento de cancer.
KR102272756B9 (ko) 정신질환 또는 중추신경계 질환 치료용 서방형 약물전달 제형 및 이의 제조방법
GEAP202416375A (en) Pro drugs of pde10 compounds
JOP20200104B1 (ar) مركبات مثبطة لـ btk
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
UA115413U (uk) Спосіб корекції імунних порушень у хворих із хронічним ексудативним середнім отитом